Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

McMaster University

$125,000.00

Industrializing vaccine stabilization technology

FY 2020-21

Summary
Our laboratory has recently identified a simple method to stabilize vaccines by storing them as films made of sugar-polymers, so that they can be stored without the need for refrigeration. By contrast, today's vaccines are unstable and need to be stored and transported in constant refrigeration - a very complex logistical problem commonly referred to as the "cold chain". Our breakthrough has attracted the attention of the media, investors and the vaccine manufacturers. We all see immense possibility to change how all vaccines are distributed globally, both in the developed world and the most remote areas of the developing world - a single solution for all. Maintaining a cold chain accounts for a substantial portion of the overall cost of vaccination. Limited capacity of the cold chain in remote areas of the world makes vaccination less accessible where it is needed the most to prevent epidemic spreading of infectious diseases. These remote areas typically have unreliable (or non-existent) power grids - this limits the ability to deliver vaccines to the most vulnerable children in the world, as these vaccines can be exposed to elevated temperatures for protracted periods of time leading to accelerated thermal degradation. The next step toward fulfilling this vision is to demonstrate its applicability to commercial vaccines and prepare for large scale manufacturing. To fulfill this, the three main goals of the this proposal are (1) adapting the technology to commercially available vaccines and we will use three major vaccines to show this (MMR, Prevnar® 13 and flu vaccines); (2) to show that the technology enables the creating of different forms to present the vaccines - as films, pills, powders, granules, powders and coatings - this will provide large scale vaccine producers the flexibility to create new products; and (3) to develop a strategy and process to bring this technology to the market. We will take these steps in constant dialogue with the world's leading vaccine manufactures to ensure the biggest impact possible.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
548768-2020
Name nom
Filipe, Carlos
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Industrializing vaccine stabilization technology
Keyword
NSERC
Application summary
Our laboratory has recently identified a simple method to stabilize vaccines by storing them as films made of sugar-polymers, so that they can be stored without the need for refrigeration. By contrast, today's vaccines are unstable and need to be stored and transported in constant refrigeration - a very complex logistical problem commonly referred to as the "cold chain". Our breakthrough has attracted the attention of the media, investors and the vaccine manufacturers. We all see immense possibility to change how all vaccines are distributed globally, both in the developed world and the most remote areas of the developing world - a single solution for all. Maintaining a cold chain accounts for a substantial portion of the overall cost of vaccination. Limited capacity of the cold chain in remote areas of the world makes vaccination less accessible where it is needed the most to prevent epidemic spreading of infectious diseases. These remote areas typically have unreliable (or non-existent) power grids - this limits the ability to deliver vaccines to the most vulnerable children in the world, as these vaccines can be exposed to elevated temperatures for protracted periods of time leading to accelerated thermal degradation. The next step toward fulfilling this vision is to demonstrate its applicability to commercial vaccines and prepare for large scale manufacturing. To fulfill this, the three main goals of the this proposal are (1) adapting the technology to commercially available vaccines and we will use three major vaccines to show this (MMR, Prevnar® 13 and flu vaccines); (2) to show that the technology enables the creating of different forms to present the vaccines - as films, pills, powders, granules, powders and coatings - this will provide large scale vaccine producers the flexibility to create new products; and (3) to develop a strategy and process to bring this technology to the market. We will take these steps in constant dialogue with the world's leading vaccine manufactures to ensure the biggest impact possible.